Immunologic rheumatic disorders

Amy Joseph, Richard Brasington, Leslie Kahl, Prabha Ranganathan, Tammy P. Cheng, John Atkinson

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

We provide the basics for clinicians who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases (ie, RA, seronegative spondyloarthropathy, SLE, antiphospholipid syndrome, Sjögren syndrome, scleroderma, and polymyositis/dermatomyositis) will be covered. In the past decade, treatment for RA and seronegative spondyloarthropathy has substantially improved. Their treatment has been revolutionized by the use of methotrexate and, more recently, TNF inhibitors, T-cell costimulation modulators, and B-cell depletion. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome, SLE, or scleroderma can be identified and then blocked, as in the example of TNF inhibitors in patients with RA, more specific treatments will become available. Thus RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume125
Issue number2 SUPPL. 2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Spondylarthropathies
Therapeutics
Dermatomyositis
Antiphospholipid Syndrome
Synovitis
Rheumatic Diseases
Methotrexate
B-Lymphocytes
Joints
T-Lymphocytes

Keywords

  • antiphospholipid syndrome
  • dermatomyositis, and inclusion-body myositis
  • juvenile rheumatoid arthritis
  • Rheumatoid arthritis
  • scleroderma polymyositis
  • seronegative spondyloarthritis
  • Sjögren syndrome
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Joseph, A., Brasington, R., Kahl, L., Ranganathan, P., Cheng, T. P., & Atkinson, J. (2010). Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology, 125(2 SUPPL. 2). https://doi.org/10.1016/j.jaci.2009.10.067

Immunologic rheumatic disorders. / Joseph, Amy; Brasington, Richard; Kahl, Leslie; Ranganathan, Prabha; Cheng, Tammy P.; Atkinson, John.

In: Journal of Allergy and Clinical Immunology, Vol. 125, No. 2 SUPPL. 2, 02.2010.

Research output: Contribution to journalArticle

Joseph, A, Brasington, R, Kahl, L, Ranganathan, P, Cheng, TP & Atkinson, J 2010, 'Immunologic rheumatic disorders', Journal of Allergy and Clinical Immunology, vol. 125, no. 2 SUPPL. 2. https://doi.org/10.1016/j.jaci.2009.10.067
Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. Journal of Allergy and Clinical Immunology. 2010 Feb;125(2 SUPPL. 2). https://doi.org/10.1016/j.jaci.2009.10.067
Joseph, Amy ; Brasington, Richard ; Kahl, Leslie ; Ranganathan, Prabha ; Cheng, Tammy P. ; Atkinson, John. / Immunologic rheumatic disorders. In: Journal of Allergy and Clinical Immunology. 2010 ; Vol. 125, No. 2 SUPPL. 2.
@article{85d76ad0bfad4c8e9cc98672443e557c,
title = "Immunologic rheumatic disorders",
abstract = "We provide the basics for clinicians who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases (ie, RA, seronegative spondyloarthropathy, SLE, antiphospholipid syndrome, Sj{\"o}gren syndrome, scleroderma, and polymyositis/dermatomyositis) will be covered. In the past decade, treatment for RA and seronegative spondyloarthropathy has substantially improved. Their treatment has been revolutionized by the use of methotrexate and, more recently, TNF inhibitors, T-cell costimulation modulators, and B-cell depletion. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being {"}elimination of synovitis equals elimination of joint destruction.{"} The hope is that if the major mediators of Sj{\"o}gren syndrome, SLE, or scleroderma can be identified and then blocked, as in the example of TNF inhibitors in patients with RA, more specific treatments will become available. Thus RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.",
keywords = "antiphospholipid syndrome, dermatomyositis, and inclusion-body myositis, juvenile rheumatoid arthritis, Rheumatoid arthritis, scleroderma polymyositis, seronegative spondyloarthritis, Sj{\"o}gren syndrome, systemic lupus erythematosus",
author = "Amy Joseph and Richard Brasington and Leslie Kahl and Prabha Ranganathan and Cheng, {Tammy P.} and John Atkinson",
year = "2010",
month = "2",
doi = "10.1016/j.jaci.2009.10.067",
language = "English (US)",
volume = "125",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - Immunologic rheumatic disorders

AU - Joseph, Amy

AU - Brasington, Richard

AU - Kahl, Leslie

AU - Ranganathan, Prabha

AU - Cheng, Tammy P.

AU - Atkinson, John

PY - 2010/2

Y1 - 2010/2

N2 - We provide the basics for clinicians who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases (ie, RA, seronegative spondyloarthropathy, SLE, antiphospholipid syndrome, Sjögren syndrome, scleroderma, and polymyositis/dermatomyositis) will be covered. In the past decade, treatment for RA and seronegative spondyloarthropathy has substantially improved. Their treatment has been revolutionized by the use of methotrexate and, more recently, TNF inhibitors, T-cell costimulation modulators, and B-cell depletion. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome, SLE, or scleroderma can be identified and then blocked, as in the example of TNF inhibitors in patients with RA, more specific treatments will become available. Thus RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

AB - We provide the basics for clinicians who might be called on to consider the diagnosis of diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in their practice. We will emphasize clinical recognition and first-line laboratory testing. Only characteristics of the classic rheumatic inflammatory diseases (ie, RA, seronegative spondyloarthropathy, SLE, antiphospholipid syndrome, Sjögren syndrome, scleroderma, and polymyositis/dermatomyositis) will be covered. In the past decade, treatment for RA and seronegative spondyloarthropathy has substantially improved. Their treatment has been revolutionized by the use of methotrexate and, more recently, TNF inhibitors, T-cell costimulation modulators, and B-cell depletion. The goal of RA treatment today is to induce a complete remission as early as possible in the disease process, with the mantra being "elimination of synovitis equals elimination of joint destruction." The hope is that if the major mediators of Sjögren syndrome, SLE, or scleroderma can be identified and then blocked, as in the example of TNF inhibitors in patients with RA, more specific treatments will become available. Thus RA has become an excellent model of this evolving paradigm. Through the identification of major mediators in its pathogenesis, novel and highly efficacious therapeutic agents have been developed.

KW - antiphospholipid syndrome

KW - dermatomyositis, and inclusion-body myositis

KW - juvenile rheumatoid arthritis

KW - Rheumatoid arthritis

KW - scleroderma polymyositis

KW - seronegative spondyloarthritis

KW - Sjögren syndrome

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=76749117491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749117491&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2009.10.067

DO - 10.1016/j.jaci.2009.10.067

M3 - Article

VL - 125

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2 SUPPL. 2

ER -